Biotechnology company Countervail Corporation has been awarded a $343,000 grant to develop its pretreatment against nerve agents.

The grant is a Fast Track SBIR Phase II grant from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health. The grant follows a phase I SBIR grant researching the company’s AverTox as an antidote protecting against exposure to organophosphorous-based nerve agents. The toxins in these nerve agents are found in chemical agents such as Soman, Sarin, and VX gas.

Charlotte-based Countervail was formed in 2007. The company researches treatments that protect the military and civilians from chemical and biological threats.